BMS-986515

N/A

Report date: 2025/08/13 20:02:02

Base Information

Drug NameBMS-986515

Drug Alias NameAllogeneic CD19-targeted Chimeric Antigen Receptor (CAR) T Cells therapy (Juno Therapeutics)BMS-986515

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaUnited StatesPoland +[10]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesJuno Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesJuno Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A